Davis Capital Management
RCUS icon

Davis Capital Management’s Arcus Biosciences RCUS Stock Holding History

Davis Capital Management’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$103 Hold
4
– – ﹤0.01% 1026
2026
Q2 		$123 Buy
+4
New +$99 ﹤0.01% 1014

Other funds holding RCUS

New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return
Tema ETFs
Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return
Louisiana State Employees Retirement System
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.56B AUM 41.43% 1-Year Est. Return
Amalgamated Bank
Amalgamated Bank New York $14.3B AUM 35.81% 1-Year Est. Return
Yousif Capital Management
Yousif Capital Management Bloomfield Hills, Michigan $8.87B AUM 34.1% 1-Year Est. Return
State of Alaska Department of Revenue
State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return
Mutual of America Capital Management
Mutual of America Capital Management New York $10.1B AUM 33.74% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

Davis Capital Management's RCUS Position: Q3 2026 in Review

Davis Capital Management held its Arcus Biosciences (RCUS) position steady in Q3 2026 at 4 shares worth $103. The position accounts for ﹤0.01% of the portfolio, ranked #1026.

Davis Capital Management first reported a position in RCUS in Q2 2026 and has held it in 2 quarters since. The position peaked at $123 in Q2 2026. 33 funds tracked by Wall St. Rank hold RCUS as of Q3 2026.

  • Davis Capital Management held 4 shares of Arcus Biosciences worth $103 as of Q3 2026.
  • Davis Capital Management left its Arcus Biosciences share count unchanged in Q3 2026.
  • Arcus Biosciences made up ﹤0.01% of Davis Capital Management's portfolio in Q3 2026, its #1026 holding.
  • Davis Capital Management first reported a position in Arcus Biosciences in Q2 2026 and has held it in 2 quarters since.
  • Davis Capital Management's Arcus Biosciences position peaked at $123 in Q2 2026.
  • 33 funds tracked by Wall St. Rank held Arcus Biosciences as of Q3 2026.

Based on Davis Capital Management's 13F filing for Q3 2026, filed 8 Oct 2026.